CDSCO Warns Pharma Firms Against Misleading Promotion of Weight-Loss Drugs
India’s drug regulator, the Central Drugs Standard Control Organisation (CDSCO), has issued an advisory asking pharmaceutical companies to avoid misleading promotion of prescription medicines used for obesity treatment. The regulator emphasized that drugs meant for weight management, including certain anti-diabetic and metabolic medicines, must not be advertised directly or indirectly to the public.
According to CDSCO, some companies have been using surrogate advertising, digital campaigns, and influencer marketing to promote prescription-only medicines. Such practices can mislead people into believing these drugs offer guaranteed weight loss without medical supervision.
The advisory reminds companies to strictly follow provisions under the Drugs and Cosmetics Act, 1940 and the Drugs Rules, 1945, which prohibit advertising of prescription medicines to the public.
CDSCO stressed that obesity should be managed through proper medical consultation, lifestyle changes, diet, and exercise, and warned that violations could invite regulatory action.
5-Point Quick Summary
Central Drugs Standard Control Organisation (CDSCO) issued an advisory to pharma companies on weight-loss drug promotions.
Companies were warned not to advertise prescription obesity medicines to the public.
The regulator flagged misleading promotions through social media, influencers, and surrogate advertising.
Firms must comply with the Drugs and Cosmetics Act, 1940 and Drugs Rules, 1945.
CDSCO stressed that obesity treatment should involve medical supervision and lifestyle changes, not marketing claims.